Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification. Issue 6 (17th March 2011)

• Record Type: Journal Article
• Authors: Lee, Andrew H S; Key, Heather P; Bell, Jane A; Hodi, Zsolt; Ellis, Ian O
• Is Part Of: Journal of clinical pathology. Volume 64:Issue 6(2011)
• Page Start: 490
• Page End: 492
• Publication Date: 2011-03-17
• Subjects: Breast cancer -- breast carcinoma -- HER2 -- immunohistochemistry -- in-situ hybridisation; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.2011.089177
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Aim: HER2 status is vital for selecting breast cancer patients for trastuzumab treatment. One recommended approach is to assess immunohistochemical staining and then perform in situ hybridisation on those tumours with a borderline (2+) immunohistochemical result. This audit aimed to assess the value of the percentage of immunohistochemical staining in 2+ tumours in selecting tumours for in-situ hybridisation. Methods: HER2 immunohistochemistry and in situ hybridisation was performed according to UK guidelines. The percentage of complete membrane staining of invasive carcinoma cells for HER2 was recorded as part of routine reporting. Results: 191 (11%) of 1735 invasive carcinomas were scored as 3+. 419 (24%) were scored as 2+. 57 of 413 2+ carcinomas (14%) were amplified (ratio of HER2 to chromosome 17≥2.0). The frequency of amplification was related to the percentage of complete membrane staining: eight of 149 (5%) with 10–19% membrane staining, 11 of 93 (12%) with 20–29% staining, 26 of 150 (17%) with 30–79% staining and 12 of 21 (57%) with 80–100% staining. Conclusions: This audit suggests that increasing the threshold for 2+ from 10% to 20% complete membrane staining would reduce the number of in-situ hybridisation tests by 36%, but reduce the detection of amplified tumours by 14%.